

## Redefining Sleep Disorder Therapy

06 July 2015 | Analysis | By BioSpectrum Bureau

### Redefining Sleep Disorder Therapy



#### Singapore:

##### **RESMED, Australia**

**Chairman:** Dr Peter C Farrell

**Revenue:** \$1437 mn

**Business:** Manufacturing devices for sleep disorders

Resmed, a global name in medical devices for managing sleep-disordered breathing (SDB), obstructive sleep apnea, or OSA, and other respiratory disorders that occur during sleep, clocked revenue of \$1437.1 million.

The company continues to invest in SDB as the market is expected to pick up in future due to increasing awareness of sleep related diseases and their role in cardiac, neurologic, metabolic and related disorders. Capitalizing on the growth of SDB market, Resmed launched series of devices in 2014 including AirFit P10 nasal pillows system, AirFit N10 nasal mask and AirFit F10 full-face mask.

Focusing on innovation, ResMed invested around \$118.2 million on R&D, approx. eight percent of the net revenue in 2014. It marginally declined from 2013 when the company spent \$120.1 million. The company bagged two Red Dot Product Design Awards for 2014, for its AirFit P10 nasal pillows mask and soon-to-be-launched Astral 150 life support ventilator.

Creating a strong foothold in the Asia Pacific market, ResMed launched a platform of portable and lightweight life support ventilators Astral 100 and Astral 150. ResMed's Astral life support ventilators enables mobility and ease of use for patients suffering from neuromuscular disease, chronic obstructive pulmonary disease (COPD), and other adult and childhood breathing disorders.

